Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 T-Cell Receptor (TCR) therapy
- Development stage
- Unknown
- Lead developer
- Adaptimmune Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NY-ESO-1 T-Cell Receptor (TCR) therapy is a cell therapy that involves engineering T cells to express a high-affinity T-cell receptor (TCR) specific for the NY-ESO-1 cancer-testis antigen. These engineered T cells are designed to recognize and destroy cancer cells presenting the NY-ESO-1 peptide in the context of HLA-A2. The therapy has shown feasibility and antitumor responses in patients with multiple myeloma in a Phase I/II clinical trial. A simplified "single editing" (SE) approach, which disrupts only the endogenous TCR alpha chain, has been developed to improve safety and manufacturing feasibility, reducing alloreactivity while maintaining potent antitumor activity. The therapy was developed by Adaptimmune and Penn Medicine.
- Other names
- NY-ESO-1 engineered CD3 T cellsNY-ESO1 engineered CD3 T cellsNY-ESO 1 engineered CD3 T cellsNY-ESO-1–redirected T cellsNY-ESO-1 transferred lymphocytesNY-ESO1 transferred lymphocytesNY-ESO 1 transferred lymphocytesNY-ESO-1 SE cellsNY-ESO1 SE cellsNY-ESO 1 SE cells
02
Targets
LAGE-1/HLA-A*02:01 (L antigen family member 1 peptide presented by human leukocyte antigen A*02:01)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on NY-ESO-1 T-Cell Receptor (TCR) therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 T-Cell Receptor (TCR) therapy.